Retraction Note: Letter to Editor, “The effects of dabrafenib and/or trametinib treatment in Braf V600mutant glioma: a systematic review and metaanalysis”

被引：0
|
作者：
Hethesh Chellapandian [1 ]
Sivakamavalli Jeyachandran [1 ]
机构：
[1] Saveetha Dental College and Hospital,Lab in Biotechnology and Biosignal Transduction, Department of Orthodontics
[2] Saveetha Institute of Medical and Technical Sciences (SIMATS),undefined
来源：
Neurosurgical Review | / 48卷 / 1期
关键词：
D O I：
10.1007/s10143-025-03284-9
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
相关论文
共 50 条
  • [1] Letter to Editor, "The effects of dabrafenib and/or trametinib treatment in Braf V600mutant glioma: a systematic review and metaanalysis"
    Chellapandian, Hethesh
    Jeyachandran, Sivakamavalli
    NEUROSURGICAL REVIEW, 2024, 47 (01)
  • [2] Letter to editor: The efects of dabrafenib and/or trametinib treatment in Braf V600-mutant glioma: a systematic review and meta-analysis
    Bin Mujtaba, Saib
    Mughal, Zaib Un Nisa
    Malik, Abdul
    NEUROSURGICAL REVIEW, 2024, 47 (01)
  • [3] The effects of dabrafenib and/or trametinib treatment in Braf V600-mutant glioma: a systematic review and meta-analysis
    Lei, Jun
    Liu, Yanhui
    Fan, Yingjun
    NEUROSURGICAL REVIEW, 2024, 47 (01)
  • [4] Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations
    Bouffet, Eric
    Hansford, Jordan R.
    Garre, Maria Luisa
    Hara, Junichi
    Plant-Fox, Ashley
    Aerts, Isabelle
    Locatelli, Franco
    van der Lugt, Jasper
    Papusha, Ludmila
    Sahm, Felix
    Tabori, Uri
    Cohen, Kenneth J.
    Packer, Roger J.
    Witt, Olaf
    Sandalic, Larissa
    Bento Pereira da Silva, Ana
    Russo, Mark
    Hargrave, Darren R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (12): : 1108 - 1120
  • [5] Combined BRAF and MEK Inhibition with Dabrafenib and Trametinib in BRAF V600-mutant colorectal cancer
    Loir, E.
    Cochereau, D.
    ONCOLOGIE, 2016, 18 (9-10) : 565 - 566
  • [6] Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
    Corcoran, Ryan B.
    Atreya, Chloe E.
    Falchook, Gerald S.
    Kwak, Eunice L.
    Ryan, David P.
    Bendell, Johanna C.
    Hamid, Omid
    Messersmith, Wells A.
    Daud, Adil
    Kurzrock, Razelle
    Pierobon, Mariaelena
    Sun, Peng
    Cunningham, Elizabeth
    Little, Shonda
    Orford, Keith
    Motwani, Monica
    Bai, Yuchen
    Patel, Kiran
    Venook, Alan P.
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4023 - +
  • [7] Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma
    Bouffet, Eric
    Geoerger, Birgit
    Moertel, Christopher
    Whitlock, James A.
    Aerts, Isabelle
    Hargrave, Darren
    Osterloh, Lisa
    Tan, Eugene
    Choi, Jeea
    Russo, Mark
    Fox, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 664 - +
  • [8] Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF V600 Mutation
    Dhillon, Sohita
    TARGETED ONCOLOGY, 2016, 11 (03) : 417 - 428
  • [9] Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
    Subbiah, Vivek
    Kreitman, Robert J.
    Wainberg, Zev A.
    Cho, Jae Yong
    Schellens, Jan H. M.
    Soria, Jean Charles
    Wen, Patrick Y.
    Zielinski, Christoph
    Cabanillas, Maria E.
    Urbanowitz, Gladys
    Mookerjee, Bijoyesh
    Wang, Dazhe
    Rangwala, Fatima
    Keam, Bhumsuk
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (01) : 7 - +
  • [10] First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma
    Kim, Chang Gon
    Kim, Miso
    Hwang, Jieon
    Kim, Seung Tae
    Jung, Minkyu
    Kim, Kyoo Hyun
    Kim, Kyung Hwan
    Chang, Jee Suk
    Koom, Woong Sub
    Roh, Mi Ryung
    Chung, Kee Yang
    Kim, Tae Min
    Kim, Sang Kyum
    Lee, Jeeyun
    Shin, Sang Joon
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (05) : 989 - 996
12345